- Home
- JBGS vs AGIO Comparison
JBGS vs AGIO Comparison
Compare JBGS & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JBGS
- AGIO
- Stock Information
- Founded
- JBGS 2016
- AGIO 2007
- Country
- JBGS United States
- AGIO United States
- Employees
- JBGS 645
- AGIO N/A
- Industry
- JBGS Real Estate Investment Trusts
- AGIO Biotechnology: Pharmaceutical Preparations
- Sector
- JBGS Real Estate
- AGIO Health Care
- Exchange
- JBGS Nasdaq
- AGIO Nasdaq
- Market Cap
- JBGS 1.3B
- AGIO 1.4B
- IPO Year
- JBGS 2017
- AGIO 2013
- Fundamental
- Price
- JBGS $17.84
- AGIO $34.41
- Analyst Decision
- JBGS Sell
- AGIO Buy
- Analyst Count
- JBGS 2
- AGIO 6
- Target Price
- JBGS $16.00
- AGIO $58.60
- AVG Volume (30 Days)
- JBGS 1.5M
- AGIO 579.1K
- Earning Date
- JBGS 07-29-2025
- AGIO 07-31-2025
- Dividend Yield
- JBGS 3.96%
- AGIO N/A
- EPS Growth
- JBGS N/A
- AGIO N/A
- EPS
- JBGS N/A
- AGIO 11.45
- Revenue
- JBGS $520,825,000.00
- AGIO $37,035,000.00
- Revenue This Year
- JBGS N/A
- AGIO $22.30
- Revenue Next Year
- JBGS $2.71
- AGIO $219.19
- P/E Ratio
- JBGS N/A
- AGIO $2.97
- Revenue Growth
- JBGS N/A
- AGIO 25.96
- 52 Week Low
- JBGS $13.28
- AGIO $23.42
- 52 Week High
- JBGS $18.86
- AGIO $62.58
- Technical
- Relative Strength Index (RSI)
- JBGS 58.04
- AGIO 59.47
- Support Level
- JBGS $17.58
- AGIO $33.62
- Resistance Level
- JBGS $18.50
- AGIO $35.82
- Average True Range (ATR)
- JBGS 0.61
- AGIO 1.38
- MACD
- JBGS -0.04
- AGIO 0.03
- Stochastic Oscillator
- JBGS 55.59
- AGIO 52.52
About JBGS JBG SMITH Properties
JBG SMITH Properties is a real estate investment trust based in the United States. It owns, operates, invests in, and develops real estate assets concentrated in amenity-rich, metro-served submarkets in and around Washington, DC. In addition, the company also provides fee-based real estate services to legacy funds through its third-party real estate services business. The operating segments of the company are commercial, multifamily, and third-party asset management and real estate services. It generates maximum revenue from the commercial segment.
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.